Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Medmira
(TSV:
MIR
)
0.0800
UNCHANGED
Streaming Delayed Price
Updated: 9:30 AM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,000
Open
0.0800
Bid (Size)
0.0800 (150)
Ask (Size)
0.0850 (560)
Prev. Close
0.0800
Today's Range
0.0800 - 0.0800
52wk Range
0.0700 - 0.1350
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MedMira Announces the appointment of Vice President of Commercial Operations
October 03, 2024
Via
ACCESSWIRE
Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada
August 13, 2024
Via
ACCESSWIRE
Performance
YTD
-23.81%
-23.81%
1 Month
-5.88%
-5.88%
3 Month
-11.11%
-11.11%
6 Month
-11.11%
-11.11%
1 Year
-5.88%
-5.88%
More News
Read More
MedMira Reports Third Quarter Results FY2024
July 02, 2024
Via
ACCESSWIRE
MedMira Announces the Hire of Vice President of Business Development
April 30, 2024
Via
ACCESSWIRE
MedMira Reports Second Quarter Results FY2024
April 01, 2024
Via
ACCESSWIRE
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
March 13, 2024
Via
ACCESSWIRE
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
February 01, 2024
Via
ACCESSWIRE
MedMira Reports First Quarter Results FY2024
December 29, 2023
Via
ACCESSWIRE
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
November 28, 2023
Via
ACCESSWIRE
Corporate Update on Clinical Evaluation of MedMira’s Products
February 01, 2024
Via
ACCESSWIRE
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
December 13, 2023
Via
ACCESSWIRE
Update on MedMira’s Regulatory Path in Canada and the USA
September 27, 2023
Via
ACCESSWIRE
Progress Update on Securities
August 30, 2023
Via
ACCESSWIRE
MedMira Reports Third Quarter Results FY2023
June 29, 2023
Via
ACCESSWIRE
MedMira Reports Second Quarter Results FY2023
April 03, 2023
Via
ACCESSWIRE
MedMira Reports First Quarter Results FY2023
December 30, 2022
Via
ACCESSWIRE
MedMira Reports FY2021 Fourth Quarter and Year End Financial Results
November 29, 2022
Via
ACCESSWIRE
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
March 14, 2023
Via
ACCESSWIRE
MedMira Enters into Partnership with Maternova for USA and Latin America
February 20, 2023
Via
ACCESSWIRE
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis
February 20, 2023
From
Maternova, Inc.
Via
Business Wire
MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
January 11, 2023
Via
ACCESSWIRE
Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)
January 03, 2023
Via
ACCESSWIRE
MedMira Introduces VYRA TriDemic
December 29, 2022
Via
ACCESSWIRE
MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test
October 14, 2022
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
